Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Sargent

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)|April 12, 2005
Lost generation. Student role models are disappearing fastAndrew Sargent
Nursing Inquiry|April 26, 2012
Reframing caring as discursive practice: a critical review of conceptual analyses of caring in nursingAndrew Sargent
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2025
Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μLSanjay Sethi, Brendan Clark, Erin K Buysman, et al.
BMC Pulmonary Medicine|September 9, 2023
Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalizationDavid Singer, Benjamin Chastek, Andrew Sargent, et al.
Diabetes Research and Clinical Practice|April 12, 2025
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular diseaseTyler J Dunn, Yong Zhu, Noelle N Gronroos, et al.
Pediatrics|January 2, 2009
Comparison of computer tomography and magnetic resonance imaging scans on the third day of life in term newborns with neonatal encephalopathyVann Chau, Kenneth John Poskitt, Michael Andrew Sargent, et al.
Clinical Therapeutics|January 18, 2025
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for DiabetesCaroline Swift, Monica Frazer, Andrew Sargent, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation HistorySanjay Sethi, Brendan Clark, Lindsay G S Bengtson, et al.
Journal of Health Economics and Outcomes Research|November 7, 2024
Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for DiabetesNoelle N Gronroos, Caroline Swift, Monica S Frazer, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2023
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterolSanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Nursing Standard (Royal College of Nursing (Great Britain) : 1987)|April 12, 2005
Lost generation. Student role models are disappearing fastAndrew Sargent
Nursing Inquiry|April 26, 2012
Reframing caring as discursive practice: a critical review of conceptual analyses of caring in nursingAndrew Sargent
International Journal of Chronic Obstructive Pulmonary Disease|October 1, 2025
Comparable Clinical Outcomes with Tiotropium/Olodaterol or Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with COPD and Blood Eosinophil Count ≤300 Cells/μLSanjay Sethi, Brendan Clark, Erin K Buysman, et al.
BMC Pulmonary Medicine|September 9, 2023
Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalizationDavid Singer, Benjamin Chastek, Andrew Sargent, et al.
Diabetes Research and Clinical Practice|April 12, 2025
Persistence with once-weekly glucagon-like peptide 1 receptor agonist therapy decreases the risk of major adverse cardiovascular events: A retrospective analysis of patients with type 2 diabetes mellitus and atherosclerotic cardiovascular diseaseTyler J Dunn, Yong Zhu, Noelle N Gronroos, et al.
Pediatrics|January 2, 2009
Comparison of computer tomography and magnetic resonance imaging scans on the third day of life in term newborns with neonatal encephalopathyVann Chau, Kenneth John Poskitt, Michael Andrew Sargent, et al.
Clinical Therapeutics|January 18, 2025
Real-World Treatment Patterns Among US Patients With Type 2 Diabetes Mellitus Initiating Treatment With Once Weekly Semaglutide for DiabetesCaroline Swift, Monica Frazer, Andrew Sargent, et al.
International Journal of Chronic Obstructive Pulmonary Disease|May 8, 2023
Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation HistorySanjay Sethi, Brendan Clark, Lindsay G S Bengtson, et al.
Journal of Health Economics and Outcomes Research|November 7, 2024
Real-World HbA1c Changes Among Type 2 Diabetes Mellitus Patients Initiating Treatment With a 1.0 Mg Weekly Dose of Semaglutide for DiabetesNoelle N Gronroos, Caroline Swift, Monica S Frazer, et al.
Journal of Managed Care & Specialty Pharmacy|May 3, 2023
Clinical and economic outcomes in patients with chronic obstructive pulmonary disease initiating maintenance therapy with tiotropium bromide/olodaterol or fluticasone furoate/umeclidinium/vilanterolSanjay Sethi, Swetha R Palli, Lindsay G S Bengtson, et al.
Pageof 2